Veradermics Incorporated MANE
- Market cap
- $5.0B
- P/E
- 0.0×
Follow MANE
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | 19 | 21 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | (26) | (70) |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | (26) | (70) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (35.94) | (111.91) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (32.14) | (96.11) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | (0.03) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (32.14) | (96.14) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | (65.78) | (162.43) |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 1 | 1 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | (24) | (72) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Capex
|
|||
| — | — | — | — | — | — | — | — | (24) | (72) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 51 | 143 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | (53) | (142) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | (48) | (121) |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (80.11%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 98.38% |
ROE
|
|||
Veradermics Incorporated (MANE) Latest News
11 Aug
Veradermics Incorporated (MANE) reported second quarter 2026 financial results and highlighted recent corporate and clinical progress. Quarterly results with clinical updates offer moderate visibility into performance and pipeline without transformative shifts.
4 Aug
Veradermics Incorporated (MANE) is positioned to disrupt the hair loss market. Positioning to disrupt the hair loss market signals major strategic moves that could significantly alter trajectory and investor sentiment.
19 Jul
Veradermics' oral hair loss drug for women achieves positive results in two months. Rapid positive results from lead oral hair loss drug strengthen regulatory and commercial outlook.
17 Jul
Veradermics presents subgroup analysis data from Phase 2/3 study ‘302’ on males with pattern hair loss at 2026 American Academy of Dermatology Innovation Academy. Phase 2/3 subgroup data presentation signals progress in hair loss treatment that may influence product development and positioning.
15 Jul
Veradermics Incorporated's hair loss pill demonstrated strong Phase II efficacy signals in women. Positive Phase II trial data for core hair loss asset can drive valuation gains and strategic momentum.
Veradermics’ Oral VDPHL01 shows positive Phase 2 results in female pattern hair loss from Study 207, preceding Phase 2/3 Study 306 readout. Positive Phase 2 data on VDPHL01 signals strong progress in Veradermics' hair loss treatment pipeline with potential to boost market position.
14 Jul
Veradermics schedules conference call to discuss Phase 2 trial results of VDPHL01 for mild-to-moderate pattern hair loss in females. Phase 2 data discussion for lead candidate signals moderate influence on development trajectory and sentiment.
21 May
Viking acquired a stake in Veradermics, underscoring the company's risky growth strategy and recent ownership changes. Viking stake signals possible short-term shifts in investor views on Veradermics growth risks without guaranteed long-term trajectory change.
20 May
Veradermics Incorporated (MANE) ranks among the top performing NYSE stocks so far in 2026. Strong 2026 stock performance signals major gains in investor sentiment and company trajectory.
3 May
Veradermics reports positive top-line Phase II/III results for its oral minoxidil pill in Study 302. Positive Phase II/III data for lead asset materially advances pipeline and valuation potential.
30 Apr
Veradermics (MANE) reported positive Phase 2/3 results for VDPHL01 in treating male pattern hair loss. Positive Phase 2/3 data on lead candidate VDPHL01 can drive major valuation gains and development momentum.
29 Apr
Veradermics Incorporated's newly listed hair loss drug shows measurable gains in hair growth. Positive hair growth data from a newly listed drug can drive valuation gains and investor interest for Veradermics.
27 Apr
Veradermics Incorporated (MANE) shares surge nearly 50% after unveiling a potential breakthrough hair loss treatment. Potential game-changer hair loss treatment triggers major stock surge and long-term growth prospects.
Veradermics shares rose 17% after positive results from a hair loss treatment trial. Positive hair loss trial results triggered a 17% stock surge for Veradermics.